Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
NCT ID: NCT04871607
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
33 participants
INTERVENTIONAL
2021-11-02
2029-10-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
NCT01476839
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
NCT02342782
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
NCT00695409
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
NCT01921387
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
NCT01468311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Evaluate the anti-lymphoma activity of the aTac-carmustine (BCNU), etoposide, cytarabine (cytosine arabinoside), and melphalan (BEAM) regimen as conditioning for autologous hematopoietic cell transplantation (AHCT); assessed by 2-year progression-free survival (PFS).
SECONDARY OBJECTIVES:
I. Estimate the overall survival (OS) probability and cumulative incidence of relapse/progression, and non-relapse mortality (NRM) at 100-days, 1-year and 2-years.
II. Summarize toxicities by type, frequency, severity, attribution, time course and duration.
III. Evaluate short and long-term complications, including: delayed engraftment (neutrophil and platelet), infection, and myelodysplasia (MDS).
EXPLORATORY OBJECTIVES:
I. Evaluate potential changes in Hodgkin lymphoma biological markers of patients treated with 90Y basiliximab BEAM via analyses of serial blood samples.
II. Assess the potential association between pre-AHCT CD25 expression levels and post-AHCT outcomes.
OUTLINE:
Patients receive 'cold' basiliximab intravenously (IV) followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours once daily (QD) and cytarabine IV over 2 hours twice daily (BID) or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive hematopoietic progenitor cell apheresis (HPC-A) product via infusion on day 0. Beginning day 5, patients receive granulocyte colony-stimulating factor (G-CSF) (or biosimilar) subcutaneously (SC) or IV until absolute neutrophil count (ANC) \> 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
After completion of study treatment, patients are followed up at 30 days, up to 2 years for response, and up to 5 years for survival.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)
Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours QD and cytarabine IV over 2 hours BID or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC \> 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
Basiliximab
Given IV
Carmustine
Given IV
Cytarabine
Given IV
Etoposide
Given IV
Genetically Engineered Hematopoietic Stem Progenitor Cells
Given via infusion
Recombinant Granulocyte Colony-Stimulating Factor
Given SC or IV
Yttrium Y 90 Basiliximab
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Basiliximab
Given IV
Carmustine
Given IV
Cytarabine
Given IV
Etoposide
Given IV
Genetically Engineered Hematopoietic Stem Progenitor Cells
Given via infusion
Recombinant Granulocyte Colony-Stimulating Factor
Given SC or IV
Yttrium Y 90 Basiliximab
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age: ≥18 years
2. Karnofsky performance status ≥ 70%
3. Life expectancy ≥ 6 months Nature of Illness and Illness Related Criteria
4. Histologically confirmed HL
5. High risk relapsed or refractory HL disease defined as having any one of the following:
* B symptoms at relapse
* Extranodal disease at relapse
* Primary refractory disease'
* Relapse \< 1 year after completion of frontline therapy
* Not in CR at the time of transplant
* Relapse after receiving PD1 blockade or brentuximab vedotin as initial therapy
6. Patients will be enrolled after collection of at least 2.0 x 106 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis.
7. Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2 (CTCAE v5).
Clinical Laboratory and Organ Function Criteria (To be performed prior to Day 1 of protocol therapy)
8. Serum creatinine ≤ 1.5 mg/dL
9. Creatinine clearance of ≥ 60 mL/min per 24 hour urine test
10. Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease)
11. AST/SGOT ≤1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL)
12. ALT/SGPT ≤ 1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL)
13. Left ventricular ejection fraction (LVEF) ≥ 50%
14. FEV1 \> 65% of predicted measured, or DLCO (diffusion capacity) ≥ 50% of predicted measured (corrected for hemoglobin).
Contraception
15. Agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least six months after the last dose of protocol therapy.
* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only).
Exclusion Criteria
2. Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation.
3. Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI.
4. Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
Other illnesses or conditions
5. Myelodysplasia or any active malignancy other than HL, or \< 5 years remission from any other prior malignancy, except non-melanoma skin cancer, localized prostate cancer or localized cervical cancer
6. Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia is excluded. This includes, but is not limited to, del(5), del(7), del(11).
7. Lymphocyte-predominant Hodgkin Lymphoma
8. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-basiliximab-DOTA.
9. Persistent marrow involvement (\>10%) with HL after salvage cytoreductive therapy and before stem cell mobilization.
10. BM harvest required to reach adequate cell dose for transplant.
11. Active Hepatitis B or C viral infection or Hepatitis B surface antigen positive
12. Positive Human Immunodeficiency Virus antibody, patients with undetectable HIV viral load with CD4 ≥ 300 and are on HAART medication are allowed
13. Patients should not have any uncontrolled illness including ongoing or active infection.
14. Patients with psychosocial circumstances or illnesses that preclude protocol participation (to be determined by P.I.)
15. Pregnant women are excluded from this study because 90Y-basiliximab/DOTA is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother 90Y-basiliximab/DOTA, breastfeeding should be discontinued if the mother is treated with 90Y-basiliximab/DOTA.
16. Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
Noncompliance
17. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
* Eligibility should be confirmed per institutional policies.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex F Herrera
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-03073
Identifier Type: REGISTRY
Identifier Source: secondary_id
20420
Identifier Type: OTHER
Identifier Source: secondary_id
20420
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.